Ligand Pharmaceuticals Q4 EPS $1.38 Beats $0.66 Estimate, Sales $28.10M Beat $25.72M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals (NASDAQ:LGND) reported Q4 earnings of $1.38 per share, surpassing the $0.66 estimate, and sales of $28.10M, exceeding the $25.72M estimate. This represents a 1.47% increase in earnings and a 44.22% decrease in sales from the same period last year.
February 27, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ligand Pharmaceuticals reported higher than expected Q4 earnings and sales, with EPS at $1.38 and sales at $28.10M, beating estimates.
The significant beat on both earnings per share and sales estimates indicates strong financial performance and operational efficiency. Despite the year-over-year decrease in sales, the substantial beat on expectations could lead to positive investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100